French cancer specialist Innate Pharma can remain independent, for now: CEO

FILE PHOTO - Herve Brailly, CEO of Innate Pharma, attends the Reuters Biotech summit in ParisBy Matthias Blamont and NoĆ«lle Mennella PARIS (Reuters) – France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April. Innate sees its independence as key to delivering optimum shareholder value in a sector characterized by big-money deals as large drugmakers look to acquire new, effective cancer treatments. In August Pfizer announced the $14 billion purchase of Medivation Inc, adding its blockbuster prostate cancer drug Xtandi to a growing oncology portfolio.

Source: Feed3

Leave a Reply

Your email address will not be published. Required fields are marked *